ICH Takes Flexible Approach On Presenting Benefit-Risk Assessment In Drug Submissions
Executive Summary
The International Council for Harmonisation's final guidance on standardizing benefit-risk information in drug submissions is expected to support regulatory decision-making through a more consistent description of information.